New research indicates that patients who discontinue blockbuster slimming jabs like Wegovy and Mounjaro can put back on shed pounds at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Findings released in a major health publication demonstrates that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users buying such treatments need to be cognizant of the danger of quick weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment weight within about a year and a half.
Comparing Approaches
The research, which looked at 37 of studies involving over 9,000 of patients, contrasted the results of GLP-1 agonists with older methods.
Scientists point out that people who shed pounds through lifestyle changes alone usually have a less rapid creep back—approximately 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Nutrition scientists believe the mechanism of the injections accounts for the heightened rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, considering the significant potential of relapse, the therapy might need to be long-term.
This opinion is supported by drug manufacturers, who note that the results "highlight the long-term character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Testimonies
Users who have stopped the medication explain a intense return of hunger.
"It was like a trigger that goes on and I was suddenly extremely hungry," recalled one woman.
This challenge is compounded if patients have not adopted lasting lifestyle or habit modifications during treatment.
Significant Use
Survey data indicate that a significant number of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is higher among women than males.
- The middle-aged age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
Ultimately, researchers stress that while these medications are effective tools for shedding pounds, they are not a permanent fix and long-term success hinges on combined lifestyle support.
